Adults with obesity often live with related conditions, like knee osteoarthritis, that may lead to pain and restricted mobility. Today we released positive results of a late-stage study involving people living with knee osteoarthritis and obesity. Read more: https://e.lilly/4iUMUkL
About us
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
- Website
- http://www.lilly.com/
External link for Eli Lilly and Company
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Indianapolis, Indiana
- Type
- Public Company
- Specialties
- Pharmaceutical Development, Pharmaceuticals, Biotech, and Biopharmaceuticals
Locations
- Primary Get directions
Lilly Corporate Center
Indianapolis, Indiana 46285, US
Employees at Eli Lilly and Company
Updates
-
Improving medicine manufacturing for patients requires significant investments in innovation. As we’ve expanded our domestic manufacturing, we’ve looked for locations and partners as focused on innovating as we are. Today, we announced plans for the third new U.S. manufacturing facility this year in Huntsville, Alabama—a place built on innovation. Learn more about the $6 billion investment and our broader manufacturing commitment here: https://e.lilly/4pzzOvU #WeAreLilly
-
An important milestone in #bloodcancer emerging from late-breaking data at #ASH25. See more from Lilly Oncology.
In a late-breaking oral presentation, Lilly will share results from a Phase 3 #bloodcancer study in previously untreated chronic lymphocytic leukemia (#CLL). Learn more here: https://e.lilly/3YhpOLw #ASH25
-
We’re pleased to welcome back Nobel Prize-winning scientist Carolyn R. Bertozzi, Ph.D., to our board of directors. Read more: https://e.lilly/4pkappL #WeAreLilly
-
-
At #ASH25, new insights for people living with #bloodcancer. See more from Lilly Oncology.
Positive results from a first-of-its-kind, head-to-head Phase 3 trial in chronic lymphocytic leukemia (#CLL) will be announced at #ASH25 and highlighted in the ASH press program. Learn more here: https://e.lilly/3Kxp6GY
-
The FDA approved an expanded indication today for an #oncology medicine in adults with relapsed or refractory CLL or SLL previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor, broadening the number of patients who may be eligible for this medicine. See more from Lilly Oncology.
Today the FDA approved an expanded indication for an #oncology medicine in adults with relapsed or refractory #chroniclymphocyticleukemia (CLL) or #smalllymphocyticlymphoma (SLL) previously treated with a covalent Bruton tyrosine kinase (BTK) inhibitor, broadening the number of patients who may be eligible for this medicine. Learn more about this significant milestone for the #bloodcancer community: https://e.lilly/49QDW5D
-
This partnership with Indiana University can help us get medicines to people who need them faster – a win for patients and for Indiana’s growing life sciences industry. #WeAreLilly
Indiana University is proud to announce a transformative five-year partnership with Eli Lilly and Company, a global leader in biopharmaceutical innovation and manufacturing. This collaboration, powered by IU Launch Accelerator for Biosciences (IU LAB), is intended to expand access to clinical trials in Indiana, strengthen Alzheimer’s disease research and care, and cultivate the next generation of scientific and clinical talent for Indiana’s rapidly growing life sciences sector. Building on decades of collaboration between the university and Lilly, this new agreement unites IU’s research and clinical expertise with Lilly’s industry leadership to accelerate discovery and improve outcomes for patients with Alzheimer’s disease, diabetes, and cancer — all while fueling growth in Indiana’s $99 billion life sciences industry. “Indiana has everything it takes to build a best-in-class system for clinical trial innovation: world-leading science, a statewide health network that reaches patients where they are, and a community that believes in turning discovery into better care,” said David A. Ricks, chair and CEO of Lilly. "Partnering with IU under Pam Whitten's leadership, we can accelerate progress by removing barriers, enrolling patients faster and delivering life-changing medicines sooner. Our goal is to transform clinical research, advancing science and improving care for Hoosiers while setting a standard that reaches far beyond our state. In doing so, Indiana strengthens its role as a global life sciences leader and models innovation that benefits patients everywhere." Learn more about this exciting, new initiative and its statewide impact: https://hey.iu.edu/ujpJz
-
-
Global Day of Service brings employees together worldwide to support initiatives that strengthen health, education and local communities. Since 2008, our teams have donated over 1.2 million service hours to more than 1,000 projects. This commitment is reflected in the work our Oncology team does with the Little Red Door Cancer Agency. Watch the full story here: https://e.lilly/4oyv5sJ #WeAreLilly
-
Obesity is rising fastest in low- and middle-income countries—and it’s fueling other serious health challenges. At United Nations General Assembly, this reality was front and center. In her latest blog, Cynthia Cardona shares why prevention, early detection and community-based care are key to creating lasting change. Together, we can build healthier, more resilient communities. #WeAreLilly
🌍 Did you know #obesity is no longer just a challenge for high-income countries? Global obesity rates have more than tripled since 1975 — affecting communities everywhere. ⚡ How can we turn the tide on obesity and #ActOnNCDs in low- and middle-income countries (LMIC)? ✍️ “Prevention, early detection, and multi-sectoral action can ease the burden of NCDs, including obesity, in resource-limited communities across low- and middle-income countries,” writes Cynthia Cardona, Vice President of Social Impact at Eli Lilly and Company, in her blog for the Global Week for Action. 🔗 Read more here: https://lnkd.in/ehShyznS
-
-
November is National Alzheimer’s Disease Awareness Month, an important reminder of why early action in brain health matters. We are committed to empowering people to make brain health part of their routine check-ups by understanding their risk factors for dementia and asking for a cognitive assessment. Through Brain Health Matters, and in partnership with advocate Julianne Moore, we are working to raise awareness and encourage conversations that can help you continue to make memories that matter: BrainHealthMatters.com